The estimated Net Worth of Rock Ventures Ii, L.P.Third... is at least $140 Milione dollars as of 2 March 2017. Rock Third owns over 2,045,294 units of Global Blood Therapeutics stock worth over $10,013,786 and over the last 8 years Rock sold GBT stock worth over $129,676,809.
Rock has made over 3 trades of the Global Blood Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently Rock sold 2,045,294 units of GBT stock worth $52,236,809 on 2 March 2017.
The largest trade Rock's ever made was selling 2,045,294 units of Global Blood Therapeutics stock on 2 March 2017 worth over $52,236,809. On average, Rock trades about 2,015,098 units every 36 days since 2016. As of 2 March 2017 Rock still owns at least 146,208 units of Global Blood Therapeutics stock.
You can see the complete history of Rock Third stock trades at the bottom of the page.
Rock's mailing address filed with the SEC is 29 Newbury St #301, Boston, MA 02116, USA.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... e Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: